Latest filing published 12 May 2025 for STRYKER CORP.
Giovanni Caforio filed 125 disclosures between February 19, 2016 and May 12, 2025, at Bristol Myers Squibb Co (120 filings, as Chairman and CEO) and at Stryker Corp (5, as Director). One sale weighs on the record: EUR 16,602,937 on February 6, 2023, followed by EUR 3,596,203 (September 15, 2022) and EUR 2,132,663 (June 13, 2022).
In all, 13 sales amount to EUR 36,156,009, with a median of EUR 1,619,105. The record is mostly non-market filings: 43 option exercises, 38 share grants and 31 filings of another kind. No purchase appears.
Activity has declined clearly over time: 23 filings in 2016, 16 to 19 a year from 2017 to 2021, then 7 in 2022, 5 in 2023, 2 in 2024 and 1 in 2025. None falls in the last twelve months. Publication comes a median of 3 days after the trade.
Within 30 days of colleagues at Bristol Myers Squibb Co, Caforio has 6, 4 and 3 own market trades, in that order, all on the same side. Names in order: Sandra Leung, Ann Powell and David Elkins V.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 162 declarations